Insider-Transaktionen

EDGAR

Scribe Therapeutics, Inc.

Von Direktoren, Führungskräften und 10-%-Eignern auf den SEC-Formularen 3, 4 und 5 gemeldete Transaktionen, aus dem XML jeder Einreichung gelesen. Codes und ihr Wortlaut stammen von der SEC.

Das Formular 4 ist innerhalb von zwei Geschäftstagen nach der Transaktion einzureichen; die jüngsten Geschäfte sind daher möglicherweise noch nicht gemeldet.

Zeitfenster: Transaktionen ab dem 18. Nov. 2025.

Käufe am offenen Markt (Code P)
9 Transaktionen, 4.730.237 Aktien
Summe Aktien × Preis je Aktie: 71.344.746,25
Verkäufe am offenen Markt (Code S)
0 Transaktionen, — Aktien

Die Summen addieren die aufgeführten eingereichten Transaktionen; sie zählen das Gemeldete und messen keine Richtung.

1–35 von 35 angezeigt

Insider-Transaktionen, neueste zuerst, wie auf den SEC-Formularen 3, 4 und 5 eingereicht
DatumMeldende PersonCodeErworben oder veräußertAktienPreis je Aktie, wie eingereichtWert (abgeleitet)Aktien danach im BesitzDirekt oder indirektKästchen zu Rule 10b5-1AnmerkungenQuelle
28. Juli 2026 Eingereicht am 28. Juli 2026Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Erworben (A)7.90518,25
144.266,25

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 144266.25.

3.088.888Indirekt (I) See footnotesNein
F2, F3, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F3 Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Einreichung öffnen 0000902664-26-003270 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
Erworben (A)2.051.742——2.051.742Indirekt (I) By AH Bio Fund II, L.P.Nein
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Einreichung öffnen 0001231919-26-000813 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
Erworben (A)697.650——697.650Indirekt (I) By AH Bio Fund III, L.P.Nein
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Einreichung öffnen 0001231919-26-000813 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Erworben (A)333.33315
4.999.995

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 4999995.

2.385.075Indirekt (I) By AH Bio Fund II, L.P.Nein
F2
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Einreichung öffnen 0001231919-26-000813 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Derivatives Wertpapier: Series A Preferred Stock — Basiswert Common Stock (2.051.742)
Veräußert (D)12.150.0030—0Indirekt (I) By AH Bio Fund II, L.P.Nein
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Einreichung öffnen 0001231919-26-000813 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Derivatives Wertpapier: Series B Preferred Stock — Basiswert Common Stock (697.650)
Veräußert (D)4.131.3440—0Indirekt (I) By AH Bio Fund III, L.P.Nein
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Einreichung öffnen 0001231919-26-000813 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Common Stock
Erworben (A)348.825——348.825Indirekt (I) See footnotesNein
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Einreichung öffnen 0000947871-26-000733 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Erworben (A)1.000.00015
15.000.000

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 15000000.

1.348.825Indirekt (I) See footnotesNein
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Einreichung öffnen 0000947871-26-000733 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Derivatives Wertpapier: Series B Preferred Stock — Basiswert Common Stock (348.825)
Veräußert (D)2.065.6720—0Indirekt (I) See footnotesNein
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Einreichung öffnen 0000947871-26-000733 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026GORDON CARL L Director
C

Conversion of derivative security

Common Stock
Erworben (A)348.825——348.825Indirekt (I) See footnotesNein
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Einreichung öffnen 0000947871-26-000734 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026GORDON CARL L Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Erworben (A)1.000.00015
15.000.000

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 15000000.

1.348.825Indirekt (I) See footnotesNein
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Einreichung öffnen 0000947871-26-000734 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026GORDON CARL L Director
C

Conversion of derivative security

Derivatives Wertpapier: Series B Preferred Stock — Basiswert Common Stock (348.825)
Veräußert (D)2.065.6720—0Indirekt (I) See footnotesNein
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Einreichung öffnen 0000947871-26-000734 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026Doudna Jennifer A 10% owner
C

Conversion of derivative security

Common Stock
Erworben (A)12.511——603.547Direkt (D) Nein
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Einreichung öffnen 0001739090-26-000010 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Juli 2026 Eingereicht am 29. Juli 2026Doudna Jennifer A 10% owner
C

Conversion of derivative security

Derivatives Wertpapier: Series A-1 Preferred Stock — Basiswert Common Stock (12.511)
Veräußert (D)74.088——0Direkt (D) Nein
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Einreichung öffnen 0001739090-26-000010 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
24. Juli 2026 Eingereicht am 28. Juli 2026Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Erworben (A)2.333.33315,00
34.999.995

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 34999995.00.

3.030.983Indirekt (I) See footnotesNein
F1, F6, F4, F5
  • F1 The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the IPO) at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC (Avoro Life Sciences) and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. (Avoro Ventures Fund and, together with Avoro Life Sciences, the Funds).
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Einreichung öffnen 0000902664-26-003270 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
24. Juli 2026 Eingereicht am 28. Juli 2026Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Erworben (A)50.00022,31
1.115.500

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1115500.00.

3.080.983Indirekt (I) See footnotesNein
F2, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Einreichung öffnen 0000902664-26-003270 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 28. Juli 2026Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (19.385) — Ausübungspreis 15
Erworben (A)19.3850—19.385Direkt (D) Nein
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002147277-26-000003 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 28. Juli 2026Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Performance-based Stock Option (Right to Buy) — Basiswert Common Stock (19.385) — Ausübungspreis 15
Erworben (A)19.3850—19.385Direkt (D) Nein
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002147277-26-000003 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Lucas Svetlana Officer: Chief Business Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Erworben (A)3.00015
45.000

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 45000.

3.000Indirekt (I) By SpouseNein— Einreichung öffnen 0001781292-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (109.426) — Ausübungspreis 15
Erworben (A)109.4260—109.426Direkt (D) Nein
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001781292-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Performance-based Stock Option (Right to Buy) — Basiswert Common Stock (109.426) — Ausübungspreis 15
Erworben (A)109.4260—109.426Direkt (D) Nein
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001781292-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (264.784) — Ausübungspreis 15
Erworben (A)264.7840—264.784Direkt (D) Nein
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002127814-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Performance-based Stock Option (Right to Buy) — Basiswert Common Stock (429.599) — Ausübungspreis 15
Erworben (A)429.5990—429.599Direkt (D) Nein
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002127814-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Watson James Dean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (14.725) — Ausübungspreis 15
Erworben (A)14.7250—14.725Direkt (D) Nein
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002130384-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Aghazadeh Behzad Director · Other: See RemarksAvoro Capital Advisors LLC Director · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (14.725) — Ausübungspreis 15
Erworben (A)14.7250—14.725Direkt (D) Nein
F1, F2, F3
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's (Dr. Aghazadeh) provision of service to the Issuer on each vesting date.
  • F2 This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company (Avoro Capital Advisors), and Avoro Ventures LLC, a Delaware limited liability company (Avoro Ventures, together with Dr. Aghazadeh and Avoro Capital Advisors, the Reporting Persons). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
  • F3 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Einreichung öffnen 0000902664-26-003254 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Bleharski Joshua Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (14.725) — Ausübungspreis 15
Erworben (A)14.7250—14.725Direkt (D) Nein
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002075052-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026GORDON CARL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (14.725) — Ausübungspreis 15
Erworben (A)14.7250—14.725Direkt (D) Nein
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001282930-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Erworben (A)1.33315
19.995

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 19995.

1.333Indirekt (I) By SpouseNein— Einreichung öffnen 0002127908-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Erworben (A)1.33315
19.995

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 19995.

1.333Indirekt (I) By ChildNein— Einreichung öffnen 0002127908-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (109.426) — Ausübungspreis 15
Erworben (A)109.4260—109.426Direkt (D) Nein
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002127908-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Juli 2026 Eingereicht am 27. Juli 2026Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Performance-based Stock Option (Right to Buy) — Basiswert Common Stock (109.426) — Ausübungspreis 15
Erworben (A)109.4260—109.426Direkt (D) Nein
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0002127908-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 28. Juli 2026Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (4.755) — Ausübungspreis 19.13
Erworben (A)4.7550—4.755Direkt (D) Nein
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Einreichung öffnen 0002147277-26-000003 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 27. Juli 2026Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (9.547) — Ausübungspreis 19.13
Erworben (A)9.5470—9.547Direkt (D) Nein
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Einreichung öffnen 0001781292-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 27. Juli 2026Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (12.969) — Ausübungspreis 19.13
Erworben (A)12.9690—12.969Direkt (D) Nein
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Einreichung öffnen 0002127814-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 27. Juli 2026Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (8.909) — Ausübungspreis 19.13
Erworben (A)8.9090—8.909Direkt (D) Nein
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Einreichung öffnen 0002127908-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten

Institutionelle Halter (Formular 13F)

Quartal zum 2026-09-30: 8.793 Einreichungen gelesen, die jüngste vom 17. Nov. 2026. Vorquartal zum 2026-06-30: 9.164 Einreichungen gelesen.

1–50 von 62 angezeigt

Institutionelle Halter, größte Position zuerst, wie eingereicht
ManagerAktien oder NennbetragWert wie eingereichtDifferenz zum VorquartalQuelle
a16z Capital Management, L.L.C. 3.082.725 SH56.737.554 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001540358-26-000014 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Avoro Capital Advisors LLC 2.598.973 SH47.834.098 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001104659-26-127608 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
RA CAPITAL MANAGEMENT, L.P. 1.802.178 SH33.169.086 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001104659-26-128411 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
ORBIMED ADVISORS LLC 1.348.825 SH24.825.124 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001172661-26-005349 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
PERCEPTIVE ADVISORS LLC 920.341 SH16.938.876 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001012975-26-001063 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
ARK Investment Management LLC 786.921 SH14.483.278 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001104659-26-126785 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
BAKER BROS. ADVISORS LP 688.691 SH12.675.358 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001104659-26-128308 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
PRICE T ROWE ASSOCIATES INC /MD/ Teilweise unter einem anderen Manager gemeldet684.706 SH12.603 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000080255-26-000736 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
BlackRock, Inc. Teilweise unter einem anderen Manager gemeldet679.786 SH12.511.461 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0002012383-26-003985 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Sanofi 500.000 SH9.202.500 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001193125-26-448717 Eingereicht am 5. Nov. 2026 Diese Zeile anfechten
VANGUARD CAPITAL MANAGEMENT LLC 407.630 SH7.502.430 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0002100119-26-001711 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
FRANKLIN TEMPLETON INC Teilweise unter einem anderen Manager gemeldet380.019 SH6.376.719 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000038777-26-000291 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
ADAGE CAPITAL PARTNERS GP, L.L.C. 380.000 SH6.993.900 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001172661-26-005200 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
FARALLON CAPITAL MANAGEMENT, L.L.C. 380.000 SH6.993.900 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000908834-26-000540 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
GEODE CAPITAL MANAGEMENT, LLC Teilweise unter einem anderen Manager gemeldet245.412 SH4.518.022 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001214717-26-000012 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
STATE STREET CORP Teilweise unter einem anderen Manager gemeldet171.147 SH3.149.961 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000093751-26-000747 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Alyeska Investment Group, L.P. 150.000 SH2.760.750 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001172661-26-005329 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Menlo Ventures Management, L.P. 97.690 SH1.797.984 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001911541-26-000014 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
TD ASSET MANAGEMENT INC 83.342 SH1.919.366 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001193125-26-460060 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Amova Asset Management Americas, Inc. Teilweise unter einem anderen Manager gemeldet74.910 SH1.378.344 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001140361-26-043552 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Sumitomo Mitsui Trust Group, Inc. Teilweise unter einem anderen Manager gemeldet74.910 SH1.378.719 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001214659-26-013361 Eingereicht am 29. Okt. 2026 Diese Zeile anfechten
NORTHERN TRUST CORP Teilweise unter einem anderen Manager gemeldet74.721 SH1.375.240 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000073124-26-000067 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
UBS Group AG Teilweise unter einem anderen Manager gemeldet71.067 SH1.307.988 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001610520-26-000121 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
VANGUARD PORTFOLIO MANAGEMENT LLC 67.039 SH1.233.853 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0002100121-26-001150 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
VANGUARD FIDUCIARY TRUST CO 64.267 SH1.182.834 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000933478-26-000017 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Nuveen, LLC Teilweise unter einem anderen Manager gemeldet41.470 SH763.255 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000930413-26-003284 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 40.876 SH0 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001213900-26-119414 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Longaeva Partners L.P. Teilweise unter einem anderen Manager gemeldet34.034 SH626.396 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001193125-26-463222 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 31.644 SH582.408 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000884546-26-000417 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
BANK OF AMERICA CORP /DE/ Teilweise unter einem anderen Manager gemeldet27.589 SH507.776 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000070858-26-000589 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Point72 Asset Management, L.P. 22.771 SH419.100 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000919574-26-008126 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
WELLS FARGO COMPANY/MN Teilweise unter einem anderen Manager gemeldet22.500 SH414.112 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000072971-26-000342 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
GOLDMAN SACHS GROUP INC Teilweise unter einem anderen Manager gemeldet21.635 SH398.192 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000886982-26-000647 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Bank of New York Mellon Corp Teilweise unter einem anderen Manager gemeldet20.396 SH375.389 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001390777-26-000121 Eingereicht am 5. Nov. 2026 Diese Zeile anfechten
Focus Partners Wealth 20.025 SH368.560 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001542153-26-000021 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
SUSQUEHANNA INTERNATIONAL GROUP, LLP Teilweise unter einem anderen Manager gemeldet13.641 SH251.063 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001446194-26-000009 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
SEVEN GRAND MANAGERS, LLC 10.000 SH184.050 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001420506-26-002775 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
RHUMBLINE ADVISERS 8.897 SH163.742 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001115418-26-000015 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
MORGAN STANLEY Teilweise unter einem anderen Manager gemeldet8.536 SH157.106 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000895421-26-000309 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
DEUTSCHE BANK AG\ Teilweise unter einem anderen Manager gemeldet8.269 SH152.233 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000948046-26-000083 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
JPMORGAN CHASE CO Teilweise unter einem anderen Manager gemeldet6.028 SH138.825 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000019617-26-000404 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
MetLife Investment Management, LLC Teilweise unter einem anderen Manager gemeldet5.814 SH107.007 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001628280-26-073956 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
CITIGROUP INC Teilweise unter einem anderen Manager gemeldet4.742 SH87.277 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000831001-26-000052 Eingereicht am 4. Nov. 2026 Diese Zeile anfechten
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Teilweise unter einem anderen Manager gemeldet4.636 SH85.326 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000905148-26-004850 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4.195 SH77.209 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001398344-26-020056 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Vanguard Global Advisers, LLC 3.592 SH66.111 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001811242-26-000017 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
TEMA ETFS LLC 3.046 SH56.062 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001829126-26-011223 Eingereicht am 16. Okt. 2026 Diese Zeile anfechten
STRS OHIO 2.600 SH47.853 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000820478-26-000018 Eingereicht am 30. Okt. 2026 Diese Zeile anfechten
BNP PARIBAS FINANCIAL MARKETS Teilweise unter einem anderen Manager gemeldet2.400 SH44.172 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001166588-26-000012 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Police Firemen's Retirement System of New Jersey Teilweise unter einem anderen Manager gemeldet2.289 SH42.129 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0002040686-26-000007 Eingereicht am 9. Nov. 2026 Diese Zeile anfechten
  • Das Formular 13F umfasst nur Long-Positionen in Wertpapieren nach Section 13(f): keine Short-Positionen und keine Wertpapiere außerhalb dieser Liste.
  • Ein Manager, der für das neueste Quartal noch nicht eingereicht hat, fehlt und steht nicht bei null; die Frist beträgt bis zu 45 Tage nach Quartalsende.
  • Eine Differenz ist der Unterschied zwischen zwei Quartalsstichtagen, keine Transaktion.
  • Eine unter einem anderen Manager gemeldete Position kann auch in dessen Einreichung erscheinen; die Zeilen werden nicht addiert.
  • Positionen, die die Wertpapierliste diesem Unternehmen nicht oder nur mehrdeutig zuordnen kann, werden nicht angezeigt.

5-%-Halter (Schedule 13D und 13G)

Hier werden im strukturierten SEC-Format (ab Ende 2024) eingereichte Schedules gelesen. Frühere sind Freitext und werden nicht gelesen.

5-%-Halter, jüngstes Ereignis zuerst, wie eingereicht
HalterProzent der GattungGehaltene AktienEreignisdatumFormularQuelle
AH Bio Fund II, L.P. Common Stock, $0.001 par value per share12.62.385.075,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13GEinreichung öffnen 0001725721-26-000009 Diese Zeile anfechten
AH Equity Partners Bio II, L.L.C. Common Stock, $0.001 par value per share12.62.385.075,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13GEinreichung öffnen 0001725721-26-000009 Diese Zeile anfechten
AH Bio Fund III, L.P. Common Stock, $0.001 par value per share3.7697.650,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13GEinreichung öffnen 0001725721-26-000009 Diese Zeile anfechten
AH Equity Partners Bio III, L.L.C. Common Stock, $0.001 par value per share3.7697.650,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13GEinreichung öffnen 0001725721-26-000009 Diese Zeile anfechten
Marc L. Andreessen Common Stock, $0.001 par value per share16.33.082.725,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13GEinreichung öffnen 0001725721-26-000009 Diese Zeile anfechten
Benjamin A. Horowitz Common Stock, $0.001 par value per share16.33.082.725,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13GEinreichung öffnen 0001725721-26-000009 Diese Zeile anfechten
RA Capital Management, L.P. Common Stock, $0.001 par value per share9.61.802.178,0007/27/2026 Eingereicht am 3. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001346824-26-000210 Diese Zeile anfechten
Peter Kolchinsky Common Stock, $0.001 par value per share9.61.802.178,0007/27/2026 Eingereicht am 3. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001346824-26-000210 Diese Zeile anfechten
Rajeev Shah Common Stock, $0.001 par value per share9.61.802.178,0007/27/2026 Eingereicht am 3. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001346824-26-000210 Diese Zeile anfechten
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share9.11.714.582,0007/27/2026 Eingereicht am 3. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001346824-26-000210 Diese Zeile anfechten
ORBIMED ADVISORS LLC Common Stock7.21.348.825,0007/27/2026 Eingereicht am 29. Juli 2026SCHEDULE 13DEinreichung öffnen 0000947871-26-000732 Diese Zeile anfechten
ORBIMED CAPITAL GP VIII LLC Common Stock7.21.348.825,0007/27/2026 Eingereicht am 29. Juli 2026SCHEDULE 13DEinreichung öffnen 0000947871-26-000732 Diese Zeile anfechten
Avoro Capital Advisors LLC Common Stock, $0.001 par value per share13.782.598.973,0007/24/2026 Eingereicht am 30. Juli 2026SCHEDULE 13DEinreichung öffnen 0000902664-26-003281 Diese Zeile anfechten
Avoro Ventures LLC Common Stock, $0.001 par value per share2.60489.915,0007/24/2026 Eingereicht am 30. Juli 2026SCHEDULE 13DEinreichung öffnen 0000902664-26-003281 Diese Zeile anfechten
Aghazadeh Behzad Common Stock, $0.001 par value per share16.373.088.888,0007/24/2026 Eingereicht am 30. Juli 2026SCHEDULE 13DEinreichung öffnen 0000902664-26-003281 Diese Zeile anfechten
ELI LILLY Co Common stock, $0.001 par value per share7.31.388.161,0007/23/2026 Eingereicht am 30. Juli 2026SCHEDULE 13DEinreichung öffnen 0000059478-26-000072 Diese Zeile anfechten

Der Prozentsatz bezieht sich auf die in der Einreichung genannte Gattung, wie vom Halter angegeben. Gruppenmitglieder melden jeweils die Aktien der Gruppe; die Zeilen werden daher nicht addiert.

Was gelesen wurde

2.241.208 Einreichungen gelesen, vom 14. Juni 2004 bis 17. Nov. 2026: Formulare 3, 3/A, 4, 4/A, 5, 5/A.

Jahre können unvollständig sein, solange das Archiv noch gelesen wird. Ein Jahr mit wenigen Einreichungen hier besagt nicht, dass wenige gemacht wurden.

Gelesene Einreichungen nach Einreichungsjahr
EinreichungsjahrGelesene Einreichungen
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
2022158.941
2023199.811
2024209.823
2025235.520
2026260.174

Einreichungen aus der Zeit vor der XML-Pflicht der SEC sind aufgeführt, aber nicht ausgelesen.

Zurück zu Scribe Therapeutics, Inc.